A Phase 1/2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of Venetoclax in Japanese Subjects With Hematological Malignancies

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 23 Jun 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Venetoclax (Primary) ; Azacitidine; Azacitidine; Rituximab
Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Multiple myeloma; Non-Hodgkin's lymphoma
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Sponsors AbbVie

28 May 2021 Results (data cutoff of 10 December 2019; n=6) from Arm C; assessing safety annd efficacy of Venetoclax plus azacitidine in patients with acute myeloid leukaemia, published in the Japanese Journal of Clinical Oncology
01 Apr 2021 Status changed from active, no longer recruiting to completed.
03 Jun 2020 Planned End Date changed from 6 Feb 2020 to 24 Jan 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com